Search results
Found 1056 matches for
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.
Trials Expertise Session: The role of a Trial Manager in a Trial Management Group (TMG) *online*
Thursday, 12 June 2025, 10am to 11am
Trials Expertise Session: Communication skills in Clinical Trials for Trial Managers *online*
Wednesday, 26 March 2025, 10am to 11am
Trials Expertise Session: Site Feasibility Questionnaires (SFQ) & Site selection *Hybrid*
Wednesday, 21 May 2025, 2pm to 3pm